is developing a unique stroke therapeutic regimen modeled off of the natural human thrombolytic system . tsi s stroke drug regimen induces rapid clot dissolution using significantly smaller safer doses than is possible with drug monotherapy the standard method of treatment today . thrombolysis is the biological defense against stroke and heart attacks . the natural human system uses two proteins plasminogen activators called tpa and prourokinase prouk . these proteins bind to the surface of the occlusive clot in a specific order and trigger a cascade of events ending in the dissolution of the clot and the restoration of blood flow . in the 1980s and 1990s thanks to the development of biotechnology several thrombolytic drugs were developed and used individually as monotherapies . it is time for a new generation solution . tsi in the news april 27 2016 find out how the design of the two natural thrombolytics were intended to function in combination and not alone in a new layman summary published on atlas of science . november 18 2015 tsi llc nominated as a top biopharma project to watch in cardiovascular by elsevier business intelligence s therapeutic area partnership conference organizers . read more tsi llc nominated as a top biopharma project to watch june 2 2015 tsi llc announces a collaboration with national institute of neurological disorders and stroke ninds to test a novel thrombolytic regimen for the treatment of acute ischemic stroke in a phase iia clinical trial . read more tsi llc to collaborate with national institutes of health home company product news contact tsi copyright 2016 tsi llc